11393254-figure-01 (Clopidogrel Tablets Usp 1)
Clopidogrel Tablet
Product Images NDC 65162-414
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 65162-414). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
11393254-figure-10 (Clopidogrel Tablets Usp 10)
Clopidogrel Label (Clopidogrel Tablets Usp 11)
11393254-figure-02 (Clopidogrel Tablets Usp 2)
This appears to be a table with information related to the effect of co-administered PPI on the active metabolite AUC. The table shows the mean and 90% confidence interval for different dosages of dexansoprazole, lansoprazole, pantoprazole, and omeprazole. The last row indicates a change relative to Clopidogrel administered alone.*
11393254-figure-03 (Clopidogrel Tablets Usp 3)
This is a chart displaying the cumulative event rates for cardiovascular death, myocardial infarction, and stroke. It compares the results of a placebo and clopidogrel (both with aspirin) and shows that there is a significant difference between the two treatments with a P value of 0.00009. The x-axis shows the months of follow-up and the y-axis shows the percentage of cumulative event rates.*
11393254-figure-04 (Clopidogrel Tablets Usp 4)
This is a table presenting data related to different patient subgroups, including their age, gender, race, and medical history. The table also shows the percentage of patients who took clopidogrel versus placebo, and the hazard ratio of clopidogrel versus placebo. No additional information is available to understand the context or purpose of the study.*
11393254-figure-05 (Clopidogrel Tablets Usp 5)
This data table provides information on subgroups of patients receiving either Clopidogrel or Placebo along with other medications such as Heparin/LMWH, Aspirin, GPIIb/IIIa Antag, Beta-Blocker, and Ace Inhibitor. The table shows the number of patients in each subgroup, the percentage of patients experiencing a favorable result, and the percentage of patients experiencing an unfavorable result. The Hazard Ratio (95% CT) shows the overall effect of the medication.*
11393254-figure-06 (Clopidogrel Tablets Usp 6)
The text provides data on the mortality rate for patients receiving Placebo and Clopidogrel within up to 28 days after randomization. Placebo had 1845 deaths (8.1%), while Clopidogrel had 1726 deaths (7.5%). The proportional risk of dying for Clopidogrel was 7%, and there was a statistically significant reduction in risk (p=0.03) upon first discharge. The graph displays mortality rates over time for both treatments.*
11393254-figure-07 (Clopidogrel Tablets Usp 7)
This text appears to be a statistical analysis of a clinical trial involving two treatments, Placebo and Clopidogrel. The percentage of patients experiencing an event in the Placebo group was 10.1%, while that in the Clopidogrel group was 9.2%. The use of Clopidogrel showed a 9% proportional risk reduction compared to placebo (p=0.002). The percentage of patients exhibiting certain complications (death, re-infarction, or stroke) before first discharge was 54%. The data was collected over a period of up to 28 days with observations being made at 0, 7, 14, 21, and 28 days since randomization.*
11393254-figure-08 (Clopidogrel Tablets Usp 8)
This table presents data on the distribution of clopidogrel and placebo utilization among subgroups based on various demographic and clinical variables. The variables include gender, age, time elapsed since the onset of the event, systolic blood pressure, heart rate, and whether fibrinolytic agents were administered. For each subgroup, the number of participants taking clopidogrel and placebo are shown as well as the percentage of participants in each subgroup who took clopidogrel versus placebo. Finally, the odds ratio and 95% confidence interval for the overall distribution are provided.*
11393254-figure-09 (Clopidogrel Tablets Usp 9)
The text describes a graph or chart showing the cumulative event rate (%) for fatal or non-fatal vascular events associated with Aspirin and Clopidogrel over the course of 36 months of follow-up. The graph shows that there is a statistically significant difference in event rate between the two drugs, with the P-value being 0.045.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
